90% in UP have developed immunity against Covid: Sero survey

Meanwhile, the Union Ministry of Health and Family Welfare has written to state governments, including Uttar Pradesh, to ramp up the second dose coverage of adolescent and young persons.

covid
Photo: Unsplash/Fusion Medical Animation
IANS Lucknow
2 min read Last Updated : Feb 03 2022 | 9:54 AM IST

More than 90 per cent of the people who have taken at least one dose of a Covid-19 vaccine in Uttar Pradesh could have developed resistance against the virus, according to a sero-prevalence survey undertaken by the state health department.

Sharing the findings, Additional Chief Secretary, Health and Family Welfare, Amit Mohan Prasad said: "Samples for the survey were taken about a fortnight."

Amit Mohan Prasad said that the total number of doses administered in the state crossed 26.46 crore mark. This includes 15.82 crore first dose takers, 10. 48 crore fully vaccinated people and 15.35 crore precaution dose recipients, besides teenagers.

He also urged people due for their second or precaution dose to come forward and get inoculated and adhere to the Covid-19 prevention protocol in individual and social interest.

More than one crore teenagers in Uttar Pradesh have taken the first dose of the Covid-19 vaccine which means that over 71 per cent of the estimated eligible population in the state has received the first dose.

Meanwhile, the Union Ministry of Health and Family Welfare has written to state governments, including Uttar Pradesh, to ramp up the second dose coverage of adolescent and young persons.

In a letter to the Chief Secretary, the Ministry has asked the state to develop an effective communication strategy to draw children and youths to vaccination centres.

--IANS

amita/ksk/

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus TestsCoronavirus Vaccine

First Published: Feb 03 2022 | 9:54 AM IST

Next Story